stockrowMadrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
- Revenue
- +50.1%
- EPS
- +147.3%
- Free cash flow
- +53.5%
- Total debt
- +0.45%
Quarter to September 2026, against a year earlier
Follow MDGL
Alert me
Madrigal Pharmaceuticals, Inc. (MDGL) EV/Sales
As of 6 November 2026, Madrigal Pharmaceuticals, Inc. (MDGL) trades at a EV/Sales of 7.7×. Over the past ten years it has ranged from 0.0× (March 2025) to 27.9× (April 2025); the current reading is higher than 86% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 9.9× | (16.21%) |
| Jun 2026 | 11.8× | (9.21%) |
| Mar 2026 | 13.0× | 0.34% |
| Dec 2025 | 13.0× | (22.00%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PCVX Vaxcyte, Inc. compare | n/m |
| MDGL Madrigal Pharmaceuticals, Inc. | 7.7× |
| TGTX TG Therapeutics, Inc. compare | 10.8× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 11.3× |
| TWST Twist Bioscience Corporation compare | 16.9× |
| KRYS Krystal Biotech, Inc. compare | 17.0× |
| PTGX Protagonist Therapeutics, Inc. compare | 28.1× |
| IBRX ImmunityBio, Inc. compare | 60.3× |
| SYRE Spyre Therapeutics, Inc. compare | 7,722× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on MDGL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement